Crossmark

Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification

Crossref DOI link: https://doi.org/10.1007/s00432-023-05398-3

Published Online: 2023-09-13

Published Print: 2023-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Feng, Lijuan

Kan, Ying

Wang, Wei

Wang, Chao

Zhang, Hui

Xie, Peng

Yang, Jigang
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (82102088, 81971642)

Capital’s Funds for Health Improvement and Research (2020-2-2025)
License Information

Text and Data Mining valid from 2023-09-13

Version of Record valid from 2023-09-13
More Information

Article History

Received: 21 July 2023

Accepted: 2 September 2023

First Online: 13 September 2023

Declarations

:

: The authors have no relevant financial or non-financial interests to disclose.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Beijing Friendship Hospital, Capital Medical University (No. 2020-P2-091-02).

: Patient consent was waived due to the retrospective nature of the study. All data used in this manuscript were anonymized.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below